Annual EBITDA
-$67.75 M
-$17.53 M-34.91%
December 31, 2023
Summary
- As of February 8, 2025, JSPR annual EBITDA is -$67.75 million, with the most recent change of -$17.53 million (-34.91%) on December 31, 2023.
- During the last 3 years, JSPR annual EBITDA has fallen by -$47.07 million (-227.58%).
- JSPR annual EBITDA is now -227.58% below its all-time high of -$20.68 million, reached on December 31, 2020.
Performance
JSPR EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$19.35 M
-$3.65 M-23.28%
September 30, 2024
Summary
- As of February 8, 2025, JSPR quarterly EBITDA is -$19.35 million, with the most recent change of -$3.65 million (-23.28%) on September 30, 2024.
- Over the past year, JSPR quarterly EBITDA has dropped by -$262.00 thousand (-1.37%).
- JSPR quarterly EBITDA is now -2235.54% below its all-time high of $906.00 thousand, reached on December 31, 2020.
Performance
JSPR Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$67.27 M
-$262.00 K-0.39%
September 30, 2024
Summary
- As of February 8, 2025, JSPR TTM EBITDA is -$67.27 million, with the most recent change of -$262.00 thousand (-0.39%) on September 30, 2024.
- Over the past year, JSPR TTM EBITDA has dropped by -$3.48 million (-5.46%).
- JSPR TTM EBITDA is now -585.85% below its all-time high of -$9.81 million, reached on December 31, 2020.
Performance
JSPR TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
JSPR EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -34.9% | -1.4% | -5.5% |
| 3 y3 years | -227.6% | -1.4% | -5.5% |
| 5 y5 years | -227.6% | -1.4% | -5.5% |
JSPR EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -85.8% | at low | -64.7% | at low | -104.1% | +2.3% |
| 5 y | 5-year | -227.6% | at low | -2235.5% | at low | -585.9% | +2.3% |
| alltime | all time | -227.6% | at low | -2235.5% | at low | -585.9% | +2.3% |
Jasper Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$19.35 M(+23.3%) | -$67.27 M(+0.4%) |
| Jun 2024 | - | -$15.69 M(+6.2%) | -$67.01 M(-2.7%) |
| Mar 2024 | - | -$14.78 M(-15.2%) | -$68.86 M(+1.6%) |
| Dec 2023 | -$67.75 M(+34.9%) | -$17.44 M(-8.6%) | -$67.75 M(+6.2%) |
| Sep 2023 | - | -$19.09 M(+8.7%) | -$63.78 M(+11.6%) |
| Jun 2023 | - | -$17.55 M(+28.4%) | -$57.14 M(+11.3%) |
| Mar 2023 | - | -$13.67 M(+1.5%) | -$51.33 M(+2.2%) |
| Dec 2022 | -$50.22 M | -$13.47 M(+8.3%) | -$50.22 M(-3.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2022 | - | -$12.44 M(+5.9%) | -$51.81 M(+21.5%) |
| Jun 2022 | - | -$11.74 M(-6.5%) | -$42.64 M(+8.5%) |
| Mar 2022 | - | -$12.56 M(-16.6%) | -$39.28 M(+19.2%) |
| Dec 2021 | -$36.46 M(+76.3%) | -$15.06 M(+360.5%) | -$32.95 M(+94.0%) |
| Sep 2021 | - | -$3.27 M(-61.0%) | -$16.99 M(-30.5%) |
| Jun 2021 | - | -$8.39 M(+34.6%) | -$24.43 M(+52.3%) |
| Mar 2021 | - | -$6.23 M(-787.9%) | -$16.04 M(+63.5%) |
| Dec 2020 | -$20.68 M | $906.00 K(-108.5%) | -$9.81 M(-8.5%) |
| Sep 2020 | - | -$10.71 M | -$10.71 M |
FAQ
- What is Jasper Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Jasper Therapeutics?
- What is Jasper Therapeutics annual EBITDA year-on-year change?
- What is Jasper Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Jasper Therapeutics?
- What is Jasper Therapeutics quarterly EBITDA year-on-year change?
- What is Jasper Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Jasper Therapeutics?
- What is Jasper Therapeutics TTM EBITDA year-on-year change?
What is Jasper Therapeutics annual EBITDA?
The current annual EBITDA of JSPR is -$67.75 M
What is the all time high annual EBITDA for Jasper Therapeutics?
Jasper Therapeutics all-time high annual EBITDA is -$20.68 M
What is Jasper Therapeutics annual EBITDA year-on-year change?
Over the past year, JSPR annual EBITDA has changed by -$17.53 M (-34.91%)
What is Jasper Therapeutics quarterly EBITDA?
The current quarterly EBITDA of JSPR is -$19.35 M
What is the all time high quarterly EBITDA for Jasper Therapeutics?
Jasper Therapeutics all-time high quarterly EBITDA is $906.00 K
What is Jasper Therapeutics quarterly EBITDA year-on-year change?
Over the past year, JSPR quarterly EBITDA has changed by -$262.00 K (-1.37%)
What is Jasper Therapeutics TTM EBITDA?
The current TTM EBITDA of JSPR is -$67.27 M
What is the all time high TTM EBITDA for Jasper Therapeutics?
Jasper Therapeutics all-time high TTM EBITDA is -$9.81 M
What is Jasper Therapeutics TTM EBITDA year-on-year change?
Over the past year, JSPR TTM EBITDA has changed by -$3.48 M (-5.46%)